CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AstraZeneca plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AstraZeneca plc
1 Francis Crick Avenue
Cambridge Biomedical Campus
Phone: +44 2073045000p:+44 2073045000 CAMBRIDGE, CB2 0AA  United Kingdom Ticker: AZNAZN
Business Summary
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes-YesYes

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board MichelDemare 68 4/27/2023 9/1/2019
Chief Executive Officer, Executive Director PascalSoriot 65 10/1/2012 10/1/2012
Chief Financial Officer, Executive Director AradhanaSarin 8/1/2021 8/1/2021
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ASTRAZENECA PLC
ASTRAZENECA PLC
ASTRAZENECA SWEDEN INVESTMENTS LIMITED 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS UK
60 additional Subsidiary records available in full report.

Business Names
Business Name
AAPM SARL
Acerta Pharma B.V.
Acerta Pharma LLC
287 additional Business Names available in full report.

General Information
Number of Employees: 94,300 (As of 12/31/2024)
Outstanding Shares: 1,550,692,963 (As of 8/31/2025)
Shareholders: 63,435
Stock Exchange: LON
Federal Tax Id: 510112321
Fax Number: +44 2076048151


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 9, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!